Newsweek/Getty

Newsweek Editors

By Newsweek Editors

0

Share

Newsweek is a Trust Project member

See more of our trusted coverage when you search.Prefer Newsweek on Googleto see more of our trusted coverage when you search.


President Donald Trump has a good claim, rhetorically at least, to one of the technologies that his own movement sometimes loves to hate.

On Wednesday, Moderna shares soared after the company and Merck announced that their personalized mRNA cancer treatment had succeeded in a pivotal Phase 3 melanoma trial. It is the first positive Phase 3 result for an individualized mRNA-based cancer treatment.

Investors reacted accordingly. Moderna surged by roughly 100 percent in premarket trading Wednesday, heading toward its best day ever, while Merck jumped more than 8 percent.

Read More on Analysis

The result is, provisionally, a scientific win for Moderna. Politically, it is also potentially a win for Trump, and a complication for Robert F. Kennedy Jr. and the Make America Healthy Again movement.

Trump and mRNA

That is because Trump's own relationship with mRNA has always been stranger, and more favorable, than the vaccine politics surrounding him suggest. When a reporter pressed him last year on why his health secretary was pulling funding from "the mRNA vaccines that are the gold standard," Trump didn't defend the move. He called Operation Warp Speed, the COVID vaccine drive under his first presidency, "one of the most incredible things ever done in this country," though he cautiously added: "But, you know, that was now a long time ago."

In January 2025, just one day after returning to the White House, Trump unveiled the $500 billion Stargate artificial-intelligence project alongside tech executives including OpenAI's Sam Altman and Oracle's Larry Ellison. Trump himself steered the conversation toward cancer, asking what AI could do for medical research and "solving things, cancer, and all the different problems."

Altman predicted diseases would be cured at an "unprecedented rate."

Trump replied: "It's going to be great."

Then Ellison got specific. Once a tumor had been genetically sequenced, he said, doctors could "design a vaccine for every individual person" and manufacture "that mRNA vaccine" using AI and robotics. Trump's response after the presentation was simple: "Great. Thanks."

Eighteen months later, such a vision of the future no longer sounds quite so futuristic.

Moderna's experimental treatment works on essentially that personalized principle. It is designed around the unique mutations in an individual patient's tumor and uses mRNA to train the immune system to recognize cancer cells, producing statistically significant improvements in survival rates, according to the two companies.

The Phase 3 trial enrolled 1,137 patients whose stage IIB-IV melanoma had been removed surgically. Moderna and Merck say they will now present the detailed results at an international medical meeting and talk to regulators about filing for approval.

President Donald Trump, Softbank CEO Masayoshi Son and Oracle chairman Larry Ellison listen to Sam Altman, CEO of OpenAI, in the Roosevelt Room of the White House on January 21, 2025, in Washington, DC.

...

What Is the New Treatment, and How Does It Work?

The timeline, of course, complicates a simple pro-Trump narrative. Moderna began developing the vaccine now called intismeran autogene in 2017, during Trump's first term, but as its own research program rather than a federally funded one, unlike Operation Warp Speed.

The data that convinced both companies to commit to a trial arrived in December 2022, and the Phase 3 study that just succeeded launched in July 2023—both under President Joe Biden. So Trump's own connection to the science is rhetorical rather than operational.

Funding Cut for mRNA

That, however, brings us to Kennedy.

In August 2025, Kennedy's Department of Health and Human Services announced that BARDA (the Biomedical Advanced Research and Development Authority) would wind down 22 mRNA vaccine projects worth nearly $500 million.

Kennedy declared that the department was "moving beyond the limitations of mRNA" and toward what he called "safer, broader vaccine platforms." HHS said the decision concerned mRNA vaccines for respiratory infections such as COVID and influenza, and other uses of the technology were not affected.

As Kennedy did not cancel cancer-mRNA research, Wednesday's result does not mean that Kennedy has killed this particular therapy, nor does a melanoma trial settle arguments about mRNA vaccines for respiratory viruses.

But it makes Kennedy's sweeping rhetoric look considerably less forward-thinking. Even Jerome Adams, who served as Trump's own surgeon general during his first term, made close to this distinction when Kennedy first announced the wind-down, saying that "mRNA technology has uses that go far beyond vaccines" and that "people are going to die."

Older arguments about the performance or safety of COVID boosters do not tell anyone whether customized mRNA can teach an immune system to hunt melanoma. Therefore, Wednesday's results are a demonstration of why governments should be cautious about turning a scientific platform into a political identity.

For Moderna, the result is a potential commercial revolution. For Trump, it is something of a vindication. For RFK Jr., the shot in the arm may sting.

View 0 Comments

Request Reprint & Licensing

Submit Correction

View Editorial & AI Guidelines